natgillin/translations-raw huggingface dataset:
Reasoned objections were raised within the 60-day period laid down in the first subparagraph of Article 6(4) of Regulation (EC) No 258/97.
V roku 60 dni, ki je določen v prvem pododstavku člena 6(4) Uredbe (ES) št. 258/97, so bili vloženi upravičeni ugovori.
On 14 April 2013, the Commission consulted the European Food Safety Authority (EFSA) asking it to carry out an additional assessment for UV-treated baker's yeast as novel food ingredient in accordance with Regulation (EC) No 258/97.
Komisija se je 14. aprila 2013 posvetovala z Evropsko agencijo za varnost hrane (v nadaljnjem besedilu: EFSA) in jo prosila za dodatno oceno z UV žarki obdelanega pekovskega kvasa kot nove živilske sestavine v skladu z Uredbo (ES) št. 258/97.
On 12 December 2013, in its ‘Scientific Opinion on the safety of vitamin D-enriched UV-treated baker's yeast’ [2], EFSA concluded that UV-treated baker's yeast exhibiting an enhanced content of vitamin D2 is safe under the intended conditions of use.
EFSA je v „Znanstvenem mnenju o varnosti z vitaminom D obogatenega in z UV žarki obdelanega pekovskega kvasa“ [2] z dne 12. decembra 2013 ugotovila, da je z UV žarki obdelan pekovski kvas, ki kaže večjo vsebnost vitamina D2, varen v predvidenih pogojih uporabe.
Therefore, the opinion gives sufficient grounds to establish that UV-treated baker's yeast as a novel food ingredient complies with the criteria laid down in Article 3(1) of Regulation (EC) No 258/97.
Zato je mnenje zadosten razlog za odločitev, da z UV žarki obdelan pekovski kvas kot nova živilska sestavina izpolnjuje merila iz člena 3(1) Uredbe (ES) št. 258/97.
Directive 2002/46/EC of the European Parliament and of the Council [3] and Regulation (EC) No 1925/2006 of the European Parliament and of the Council [4] lay down specific provisions for the use of vitamins and minerals when added to food and in food supplements.
Direktiva 2002/46/ES Evropskega parlamenta in Sveta [3] in Uredba (ES) št. 1925/2006 Evropskega parlamenta in Sveta [4] določata posebne določbe za uporabo vitaminov in mineralov, kadar se dodajo živilom in prehranskim dopolnilom.
The use of UV-treated baker's yeast should be authorised without prejudice to those specific provisions.
Uporabo z UV obdelanega pekovskega kvasa bi bilo treba odobriti brez poseganja v navedene posebne določbe.
UV-treated baker's yeast as specified in Annex I may be placed on the market in the Union as a novel food ingredient for the uses defined and at the maximum levels established in Annex II without prejudice to Directive 2002/46/EC and Regulation (EC) No 1925/2006.
Z UV žarki obdelan pekovski kvas, kot je opredeljen v Prilogi I, se lahko daje na trg Unije kot nova živilska sestavina za opredeljene uporabe in v največjih količinah, ki so določene v Prilogi II, ter brez poseganja v Direktivo 2002/46/ES in Uredbo (ES) št. 1925/2006.
The designation of UV-treated baker's yeast authorised by this Decision on the labelling of the foodstuffs containing it shall be ‘vitamin D yeast’ or ‘vitamin D2 yeast’.
Poimenovanje z UV žarki obdelanega pekovskega kvasa, odobrenega s tem sklepom, na živilih, ki ga vsebujejo, je „kvas z vitaminom D“ ali „kvas z vitaminom D2“.
Done at Brussels, 24 June 2014.
Za Komisijo
Member of the Commission
UL L 43, 14.2.1997, str. 1.
OJ L 43, 14.2.1997, p. 1.
Direktiva 2002/46/ES Evropskega parlamenta in Sveta z dne 10. junija 2002 o približevanju zakonodaj držav članic o prehranskih dopolnilih (UL L 183, 12.7.2002, str. 51).
Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements (OJ L 183, 12.7.2002, p. 51).
PRILOGA I
Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of vitamins and minerals and of certain other substances to foods (OJ L 404, 30.12.2006, p. 26).
SPECIFIKACIJA Z UV ŽARKI OBDELANEGA PEKOVSKEGA KVASA
ANNEX I
Opredelitev
SPECIFICATION OF UV-TREATED BAKER'S YEAST
Pekovski kvas (Saccharomyces cerevisiae) se obdela z ultravijoličnimi žarki, da se sproži pretvorba ergosterola v vitamin D2 (ergokalciferol).
Definition
Vsebnost vitamina D2 v koncentratu kvasa varira med 1800000 – 3500000 IU vitamina D/100g (450 – 875 μg/g).
Vitamin D2 content in the yeast concentrate varies between 1800000-3500000 IU vitamin D/100 g (450-875 μg/g).
Rjavkaste barve, sipka zrnca
Tan-coloured, free-flowing granules
,7E,22E)-3S-9,10-sekoergosta-5,7,10(19),22-tetraen-3-ol
Chemical name
ergokalciferol
,7E,22E)-3S-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
Št.
Ergocalciferol
Molekulska masa
Molecular weight
Mikrobiološka merila koncentrata kvasa
396,65 g/mol
Koliformne bakterije
Microbiological criteria of the yeast concentrate
Ne več kot 1000/g
Coliforms
Ne več kot 10/g
Not more than 10/g
Ni najdeno v 25 g
Salmonellaspp.
PRILOGA II
Absent in 25 g
ODOBRENE UPORABE Z UV ŽARKI OBDELANEGA PEKOVSKEGA KVASA
ANNEX II
Kategorija živil
AUTHORISED USES OF UV-TREATED BAKER'S YEAST
Najvišja dovoljena vsebnost
Food category
S kvasom vzhajan kruh in rogljiči
Maximum use level
5 μg vitamina D2/100 g končnega proizvoda
Yeast-leavened breads and rolls
S kvasom vzhajani fini pekovski izdelki
5 μg of vitamin D2/100 g final product
Prehranska dopolnila
Yeast-leavened fine bakery wares
5 μg vitamina D2/dan
Food supplements
Ta sklep je naslovljen na družbo Lallemand SAS, 19 Rue des Briquetiers BP59, 31702 Blagnac Cedex, Francija.
of 25 June 2014
z dne 25. junija 2014
postponing the expiry date of approval of difethialone and difenacoum for use in biocidal products for product-type 14
o odložitvi datuma izteka odobritve difetialona in difenakuma za uporabo v biocidnih proizvodih za uporabo v vrsti proizvodov 14
Having regard to Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products [1], and in particular Article 14(5) thereof,
ob upoštevanju Uredbe (EU) št. 528/2012 Evropskega parlamenta in Sveta z dne 22. maja 2012 o dostopnosti na trgu in uporabi biocidnih proizvodov [1] ter zlasti člena 14(5) Uredbe,
The active substances difethialone and difenacoum were included into Annex I to Directive 98/8/EC of the European Parliament and of the Council [2] for use in biocidal products for product-type 14, and pursuant to Article 86 of Regulation (EU) No 528/2012 are considered approved under that Regulation subject to the specifications and conditions set out in Annex I to that Directive.
Aktivni snovi difetialon in difenakum sta bili vključeni v Prilogo I k Direktivi 98/8/ES Evropskega parlamenta in Sveta [2] za uporabo v biocidnih proizvodih v vrsti proizvodov 14 in se na podlagi člena 86 Uredbe (EU) št. 528/2012 štejeta za odobreni v skladu z navedeno uredbo ob upoštevanju specifikacij in pogojev iz Priloge I k navedeni direktivi.
In accordance with Article 13(1) of Regulation (EU) No 528/2012, applications have been submitted for the renewal of the approval of these active substances.
Poleg tega se zaradi teh značilnosti odobritev navedenih aktivnih snovi lahko podaljša le, če se dokaže, da je izpolnjen vsaj eden od pogojev iz prvega pododstavka člena 5(2) Uredbe (EU) št. 528/2012.
Because of the identified risks and the characteristics of the active substances difethialone and difenacoum, which render them potentially persistent, liable to bioaccumulate and toxic, or very persistent and very liable to bioaccumulate, the renewal of their approval is subject to an assessment of an alternative active substance or substances.
Komisija je začela študijo o ukrepih za zmanjšanje tveganja, ki se lahko uporabljajo za antikoagulantne rodenticide, da bi lahko predlagala ukrepe, ki so najbolj primerni za zmanjšanje tveganj, povezanih z lastnostmi navedenih aktivnih snovi.
In addition, due to these characteristics, the approval of those active substances may be renewed only if it is shown that at least one of the conditions of the first subparagraph of Article 5(2) of Regulation (EU) No 528/2012 is fulfilled.
Omenjena študija je trenutno v teku, vložnikom pa bi bilo potrebno dati možnost za podaljšanje odobritve za navedene aktivne snovi, da bi v vlogah lahko obravnavali ugotovitve iz študije.
The Commission has launched a study on the risk-mitigation measures that may be applied to anticoagulant rodenticides with a view to proposing the measures that are most suitable for mitigating the risks associated to the properties of those active substances.
Poleg tega bi bilo ugotovitve iz te študije treba upoštevati pri odločanju o podaljšanju odobritve vseh antikoagulantnih rodenticidov.
That study is currently on-going, and the possibility should be given to the applicants for the renewal of approval of those active substances to address the conclusions of the study in their application.
Da se olajšata pregled ter primerjava tveganj in koristi vseh antikoagulantnih rodenticidov kot tudi ukrepov za zmanjšanje tveganja, ki se uporabljajo zanje, bi bilo treba oceno difetialona in difenakuma odložiti do zadnjega vloženega zahtevka za podaljšanje odobritve zadnjega antikoagulantnega rodenticida.
Furthermore, the conclusions of that study should be taken into account when deciding on the renewal of the approval of all anticoagulant rodenticides.
Pričakuje se, da bodo vloge za podaljšanje odobritve zadnjih antikoagulantnih rodenticidov, in sicer brodifakuma, varfarina in natrijevega varfarinata, predložene do 31. julija 2015.
In order to facilitate the review and comparison of the risks and benefits of all anticoagulant rodenticides as well as of the risk-mitigation measures applied to them, the assessment of difethialone and difenacoum should be postponed until the last application for the renewal of the last anticoagulant rodenticide is submitted.
Posledično bo odobritev difetialona in difenakuma zaradi razlogov, na katere vložnik nima vpliva, verjetno prenehala veljati pred sprejetjem odločitve o njunem podaljšanju.
Applications for the renewal of the approval of the last anticoagulant rodenticides, namely brodifacoum, warfarin and warfarin sodium, are expected to be submitted by 31 July 2015.
Zato je primerno datum izteka odobritev navedenih aktivnih snovi odložiti za obdobje, ki je potrebno, da se omogoči preverjanje vlog.
Consequently, for reasons beyond the control of the applicants, the approval of difethialone and difenacoum is likely to expire before a decision has been taken on their renewal.
Z izjemo datuma izteka odobritve bi morali navedeni snovi ostati odobreni v skladu s specifikacijami in pogoji, navedenimi v Prilogi I k Direktivi 98/8/ES.
It is therefore appropriate to postpone the expiry date of approval of those active substances for a period of time sufficient to enable the examination of the applications.
Ukrepi iz tega sklepa so v skladu z mnenjem Stalnega odbora za biocidne pripravke –
Except for the expiry date of the approval, those substances should remain approved subject to the specifications and conditions set out in Annex I to Directive 98/8/EC.
SPREJELA NASLEDNJI SKLEP:
The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Biocidal Products,
Člen 1
HAS ADOPTED THIS DECISION:
Datum izteka odobritve difetialona in difenakuma za uporabo v biocidnih proizvodih v vrsti proizvodov 14 se odloži na 30. junij 2018.
The expiry date of approval of difethialone and difenacoum for use in biocidal products for product-type 14 shall be postponed to 30 June 2018.
Ta sklep začne veljati dvajseti dan po objavi v Uradnem listu Evropske unije.
Article 2
V Bruslju, 25. junija 2014
This Decision shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
Za Komisijo
Done at Brussels, 25 June 2014.
Predsednik
For the Commission
UL L 167, 27.6.2012, str. 1.
The President
Direktiva 98/8/ES Evropskega parlamenta in Sveta z dne 16. februarja 1998 o dajanju biocidnih pripravkov v promet (UL L 123, 24.4.1998, str. 1).
OJ L 167, 27.6.2012, p. 1.
Odobritvi se iztečeta 31. oktobra 2014 oziroma 31. marca 2015.
Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market (OJ L 123, 24.4.1998, p. 1).
V skladu s členom 13(1) Uredbe (EU) št. 528/2012 sta bili vloženi vlogi za podaljšanje odobritev teh aktivnih snovi.
establishing the position to be adopted on behalf of the European Union within the General Council of the World Trade Organization on the accession of the Islamic Republic of Afghanistan to the World Trade Organization
o stališču, ki se v imenu Evropske unije sprejme v okviru Generalnega sveta Svetovne trgovinske organizacije glede pristopa Islamske republike Afganistan k Svetovni trgovinski organizaciji
Having regard to the Treaty on the Functioning of the European Union, and in particular Article 91, Article 100(2) and the first subparagraph of Article 207(4), in conjunction with Article 218(9), thereof,
ob upoštevanju Pogodbe o delovanju Evropske unije ter zlasti člena 91, člena 100(2) in prvega pododstavka člena 207(4) v povezavi s členom 218(9) Pogodbe,
On 21 November 2004, the Government of the Islamic Republic of Afghanistan applied for accession to the Marrakesh Agreement establishing the World Trade Organization (WTO), pursuant to Article XII of that Agreement.
Vlada Islamske republike Afganistan je 21. novembra 2004 zaprosila za pristop k Marakeškemu sporazumu o ustanovitvi Svetovne trgovinske organizacije (STO) v skladu s členom XII navedenega sporazuma.
A Working Party on the accession of the Islamic Republic of Afghanistan was established on 13 December 2004 in order to reach agreement on terms of accession acceptable to the Islamic Republic of Afghanistan and all WTO Members.
Delovna skupina za pristop Islamske republike Afganistan je bila ustanovljena 13. decembra 2004, da se dogovori o pristopnih pogojih, sprejemljivih za Islamsko republiko Afganistan in vse članice STO.
The Commission, on behalf of the Union, has negotiated a comprehensive series of market opening commitments on the part of the Islamic Republic of Afghanistan which satisfy the Union's requests.
Komisija je v imenu Unije s pogajanji določila celovit sklop zavez Islamske republike Afganistan za odpiranje trga, ki izpolnjuje zahteve Unije.
Those commitments are now embodied in the Protocol of Accession of the Islamic Republic of Afghanistan to the WTO (‘the Protocol of Accession’).
Te zaveze so zdaj zajete v Protokolu o pristopu Islamske republike Afganistan k STO (v nadaljnjem besedilu: Protokol o pristopu).
Accession to the WTO is expected to make a positive and lasting contribution to the process of economic reform and sustainable development in the Islamic Republic of Afghanistan.
Pristop k STO naj bi po pričakovanjih pozitivno in trajno prispeval k procesu gospodarskih reform in trajnostnemu razvoju v Islamski republiki Afganistan.
Accordingly, it is necessary to establish the position to be adopted on the Union's behalf within the General Council of the WTO on the accession of the Islamic Republic of Afghanistan to the WTO,
Zato je treba sprejeti stališče, ki se v imenu Unije sprejme v okviru Generalnega sveta STO glede pristopa Islamske republike Afganistan k STO –
The position to be adopted on behalf of the European Union within the General Council of the World Trade Organization on the accession of the Islamic Republic of Afghanistan to the World Trade Organization is to approve the accession.
Stališče, ki se v imenu Evropske unije sprejme v okviru Generalnega sveta Svetovne trgovinske organizacije glede pristopa Islamske republike Afganistan k Svetovni trgovinski organizaciji je, da se ta pristop odobri.
Done at Luxembourg, 24 June 2014.
V Luxembourgu, 24. junija 2014
Council Decision 2014/400/CFSP
Sklep Sveta 2014/400/SZVP
of 26 June 2014
z dne 26. junija 2014
Having regard to the Treaty on European Union, and in particular Article 31(2) and Article 33 thereof,
ob upoštevanju Pogodbe o Evropski uniji ter zlasti člena 31(2) in člena 33 Pogodbe,
On 25 January 2012, the Council adopted Decision 2012/39/CFSP [2] appointing Mr Samuel ŽBOGAR as the European Union Special Representative (EUSR) in Kosovo.
Svet je 25. januarja 2012 sprejel Sklep 2012/39/SZVP [2], s katerim je Samuela ŽBOGARJA imenoval za posebnega predstavnika Evropske unije (PPEU) na Kosovu.
The mandate of the EUSR should be extended for a further period of eight months.
Mandat PPEU bi bilo treba podaljšati za nadaljnjih osem mesecev.
The EUSR will implement the mandate in the context of a situation which may deteriorate and could impede the achievement of the objectives of the Union's external action as set out in Article 21 of the Treaty,
PPEU bo mandat opravljal v razmerah, ki se lahko poslabšajo in bi lahko ovirale doseganje ciljev zunanjega delovanja Unije iz člena 21 Pogodbe –
The Council may decide that the mandate of the EUSR be terminated earlier, based on an assessment by the Political and Security Committee (PSC) and a proposal of the High Representative of the Union for Foreign Affairs and Security Policy (HR).
Politični cilji
Article 2
Mandat PPEU temelji na političnih ciljih Unije na Kosovu.
Policy objectives
Med te sodijo prevzemanje vodilne vloge pri oblikovanju stabilnega, trdnega, mirnega, demokratičnega in večetničnega Kosova;
The mandate of the EUSR shall be based on the policy objectives of the Union in Kosovo.
krepitev stabilnosti v regiji ter prispevanje k regionalnemu sodelovanju in dobrim sosedskim odnosom na Zahodnem Balkanu;
These include playing a leading role in promoting a stable, viable, peaceful, democratic and multi-ethnic Kosovo;
spodbujanje zavezanosti Kosova pravni državi in varovanju manjšin ter kulturne in verske dediščine;
strengthening stability in the region and contributing to regional cooperation and good neighbourly relations in the Western Balkans;
podpora nadaljnjemu približevanju Kosova Uniji v skladu z evropsko perspektivo regije in ustreznimi sklepi Sveta.
promoting a Kosovo that is committed to the rule of law and to the protection of minorities and of cultural and religious heritage;
Člen 3
Article 3
Da bi dosegel politične cilje, ima PPEU naslednji mandat:
Mandate
zagotavljati svetovanje in podporo Unije v političnem procesu;
In order to achieve the policy objectives, the mandate of the EUSR shall be to:
spodbujati splošno politično usklajevanje Unije na Kosovu;
offer the Union's advice and support in the political process;
okrepiti prisotnost Unije na Kosovu ter zagotoviti njeno doslednost in uspešnost;
promote overall Union political coordination in Kosovo;
vodji misije Evropske unije za krepitev pravne države na Kosovu (EULEX KOSOVO) dajati lokalne politične smernice, tudi glede političnih vidikov vprašanj, povezanih z izvršilnimi pristojnostmi;
strengthen the presence of the Union in Kosovo and ensure its coherence and effectiveness;
zagotavljati skladnost in doslednost ukrepov Unije na Kosovu, tudi z lokalnim usmerjanjem prehoda misije EULEX;
provide local political guidance to the Head of the European Union Rule of Law Mission in Kosovo (EULEX KOSOVO), including on the political aspects of issues relating to executive responsibilities;
podpirati nadaljnje približevanje Kosova Uniji v skladu z evropsko perspektivo regije, in sicer s ciljno usmerjenim javnim obveščanjem in dejavnostmi Unije za ozaveščanje, oblikovanimi za zagotovitev boljšega razumevanja in podpore javnosti Kosova glede zadev, povezanih z Unijo, vključno z delom EULEX;
ensure consistency and coherence of Union action in Kosovo, including in guiding the EULEX transition locally;
spremljati, podpirati in pospeševati napredek pri političnih, gospodarskih in evropskih prednostnih nalogah v skladu z ustreznimi institucionalnimi pristojnostmi in odgovornostmi;
support Kosovo's progress towards the Union, in accordance with the European perspective of the region, through targeted public communication and Union outreach activities designed to ensure a broader understanding and support from the Kosovo public on issues related to the Union, including the work of EULEX;
prispevati k razvoju in utrjevanju spoštovanja človekovih pravic in temeljnih svoboščin na Kosovu, tudi v zvezi z ženskami in otroki ter varstvom manjšin, v skladu s politiko Unije na področju človekovih pravic in smernicami Unije o človekovih pravicah;
monitor, assist and facilitate progress on political, economic and European priorities, in line with respective institutional competencies and responsibilities;
pomagati pri izvajanju dialoga med Beogradom in Prištino, pri katerem posreduje Unija.
contribute to the development and consolidation of respect for human rights and fundamental freedoms in Kosovo, including with regard to women and children and protection of minorities, in accordance with the Union's human rights policy and Union Guidelines on Human Rights;
Člen 4
assist in the implementation of the Belgrade-Pristina dialogue facilitated by the Union.
Izvajanje mandata
Implementation of the mandate
PVO je v prednostni povezavi s PPEU in je njegova glavna točka za stike s Svetom.
The EUSR shall work in close coordination with the European External Action Service (EEAS) and the relevant departments thereof.
Financiranje
Article 5
Referenčni finančni znesek za kritje odhodkov, povezanih z mandatom PPEU, za obdobje od 1. julija 2014 do 28. februarja 2015 znaša 1450000 EUR.
The financial reference amount intended to cover the expenditure related to the mandate of the EUSR in the period from 1 July 2014 to 28 February 2015 shall be EUR 1450000.
Državljani držav regije Zahodnega Balkana se lahko prijavijo na javne razpise.
The expenditure shall be managed in accordance with the procedures and rules applicable to the general budget of the Union.
Upravljanje odhodkov se uredi s pogodbo med PPEU in Komisijo.
Nationals of the countries of the Western Balkan region shall be allowed to tender for contracts.
PPEU za vse odhodke odgovarja Komisiji.
The management of the expenditure shall be subject to a contract between the EUSR and the Commission.
Člen 6
Article 6
Pri izvajanju mandata PPEU in prispevanju k doslednosti, prepoznavnosti in uspešnosti celotne dejavnosti Unije na Kosovu PPEU pomaga dodeljeno osebje.
Constitution and composition of the team
PPEU je v okviru svojega mandata in ustreznih razpoložljivih finančnih sredstev odgovoren za sestavo svoje ekipe.
Dedicated staff shall be assigned to assist the EUSR to implement his mandate and to contribute to the coherence, visibility and effectiveness of Union action in Kosovo overall.
Ta ekipa vključuje strokovnjake za določena politična vprašanja, kot to zahteva mandat.
Within the limits of his mandate and the corresponding financial means made available, the EUSR shall be responsible for constituting his team.
PPEU nemudoma obvesti Svet in Komisijo o sestavi svoje ekipe.
The EUSR shall keep the Council and the Commission promptly informed of the composition of his team.
Plače takega začasno dodeljenega osebja krije zadevna država članica, institucija Unije oziroma ESZD.
Member States, institutions of the Union and the EEAS may propose the secondment of staff to work with the EUSR.
PPEU se lahko dodelijo tudi strokovnjaki, ki so jih države članice začasno dodelile institucijam Unije ali ESZD.
The salary of such seconded personnel shall be covered by the Member State, the institution of the Union concerned or the EEAS, respectively.
Mednarodno pogodbeno osebje ima državljanstvo ene od držav članic.
Experts seconded by Member States to the institutions of the Union or the EEAS may also be posted to work with the EUSR.
Vse dodeljeno osebje ostane pod upravno pristojnostjo države članice ali institucije Unije, ki ga pošilja, oziroma ESZD ter opravlja svoje obveznosti in deluje v interesu mandata PPEU.
International contracted staff shall have the nationality of a Member State.
Člen 7
All seconded personnel shall remain under the administrative authority of the sending Member State, institution of the Union or the EEAS and shall carry out their duties and act in the interests of the mandate of the EUSR.
Privilegiji in imunitete PPEU in njegovega osebja